Current Opinion in Oncology was launched in 1989. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of psychiatry is divided into 15 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Editor and Section Editors for this issue.
Jean A. Klastersky
Professor Klastersky was Head of the Department of Medicine at the Institut Jules Bordet in Brussels, Belgium, and Professor of Medicine, Medical Oncology and Physical Diagnosis at the Université Libre de Bruxelles, Belgium, from 1977. He retired from these positions in 2005. Currently, he is the coordinator of the “Programme des Soins Oncologiques” for the Public Hospitals in Brussels and consultant in medical oncology at the Institut Jules Bordet, Belgium.
Professor Klastersky was an intern and resident at the University Hospitals of the Université Libre de Bruxelles between 1962 and 1965, where he gained his MD (Docteur en Médecine, Chirurgie et Accouchements). From 1967 to 1968, he was Chief-Resident at Boston City Hospital, USA, and then a Research Fellow and Assistant in Medicine at Thorndike Memorial Laboratory Harvard Medical School, USA. He became Chief of the Section of Infectious Diseases at the Institut Jules Bordet in 1970, before taking up the position of Head of the Department of Medicine in 1977.
Professor Klastersky was a founder member of the European Lung Cancer Working Party and was President from 1978 until 2003. He was President (and founder member) of the International EORTC Antimicrobial Therapy Project Group between 1979 and 1987 and the Group's Secretary General from 1987 to 2000. He was President (and founder member) of the Multinational Association for Supportive Care in Cancer (MASCC) from 1990 to 2000.
He has been Visiting Professor of Medical Oncology at the Charles University in Prague, Czech Republic, since 1994.
Professor Klastersky is a member of the American Society of Clinical Oncology, the American Association of Cancer Research, the European Society of Medical Oncology, the American Society of Microbiology, the Infectious Diseases Society of America, the International Association for the Study of Lung Cancer, the “Royale Académie de Médecine” of Belgium and various other international and national medical and/or oncological societies.
Professor Klastersky is the author of over 400 original articles, nearly 400 review articles and 17 scientific books.
He is the Editor of Current Opinion in Oncology.
Christiane Jungels, MD, is a Medical Oncologist at the Jules Bordet Institute in Brussels, Belgium. A Luxembourgish citizen, she came to Belgium in 2004 for Medical School at the Université Libre de Bruxelles (ULB), where she graduated as a Medical Doctor in 2010. She first trained in internal medicine, and later did her training in medical oncology at the Jules Bordet Institute, and graduated as a medical oncologist in 2016. She has been working in the Institute as a specialist since the end of 2016, with a primary interest the management of rare tumors, including sarcomas and endocrine tumors. Besides coordinating projects focusing on rare tumors, her main activity is clinical research, especially early drug development for patients with solid tumors with a special commitment to rare tumors. She is local Principal Investigator for several phase 1 trials and co-investigator in many phase 1 to 3 studies.
She is member of the Belgian Society for Medical Oncology (BSMO) and the European Society for Medical Oncology (ESMO).
Robert Pirker obtained a master's degree in biochemistry in 1978 and his medical degree in 1979 from the University of Vienna, Austria. Robert Pirker trained in internal medicine, hemato-oncology and nuclear medicine at the University of Vienna. He also worked as NIH Visiting Fellow at the Laboratory of Molecular Biology (Chief: Dr Ira Pastan), National Cancer Institute, Bethesda, MD, USA (1983–86).
His research interests are chemotherapy and targeted therapy of lung cancer, drug resistance mechanisms of cancer, and management of chemotherapy-induced anemia. He has published more than 200 articles, reviews or book chapters. He was a member of the IASLC Board of Directors (2015–2019). He was Congress President of the 8th and 14th Central European Lung Cancer Congresses, Chair of the Scientific Committee of the European Multidisciplinary Conference on Thoracic Oncology in 2009, and Conference President of the IASLC 17th World Conference on Lung Cancer in 2016 in Vienna. He is the current President of the Central European Lung Cancer Association and as Professor of Medicine teaches Medical and Experimental Oncology at the Medical University of Vienna, Austria.
Professor Zhou is Director of Oncology center of Tongji University, China, and Director of Department of Medical Oncology of Shanghai Pulmonary Hospital. He is Board Director of IASLC, Executive Committee Member of Chinese Society of Clinical Oncology, Chairman of Non-small Cell Lung Cancer Expert committee of CSCO and so on. Prof. Zhou is the Editor-in-Chief of the journal Translation Lung Cancer Research, Associate Editor of Lung Cancer and Chinese Journal of Lung Cancer etc.
His work was mainly focused on immunotherapy, targeted therapy, anti-angiogenesis, and the likes and has made great contribution to progress in lung cancer treatment. He is leading PI of several famous multi-center clinical trials, including OPTIMAL, BEYOND, CAMEL, Keynote-033. He is also actively involved in several global influential trials, including ALESIA, IPASS, etc.
He has published over 150 peer-reviewed papers in journal like Lancet Oncology, Lancet Respiratory Medicine and Journal of Clinical Oncology. He won 1st Award of Science and Technology Progress of Shanghai in 2018 and 2nd Award of Science and Technology Progress of China in 2019.